UNLABELLED: The goal of this study was to evaluate the (18)F-labeled nonnatural amino acid (S)-2-amino-3-[1-(2-(18)F-fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid ((18)F-AFETP) as a PET imaging agent for brain tumors and to compare its effectiveness with the more-established tracers O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) and (18)F-FDG in a murine model of glioblastoma. The tracer (18)F-AFETP is a structural analog of histidine and is a lead compound for imaging cationic amino acid transport, a relatively unexplored target for oncologic imaging. METHODS: (18)F-AFETP was prepared using the click reaction. BALB/c mice with intracranially implanted delayed brain tumor (DBT) gliomas (n = 4) underwent biodistribution and dynamic small-animal PET imaging for 60 min after intravenous injection of (18)F-AFETP. Tumor and brain uptake of (18)F-AFETP were compared with those of (18)F-FDG and (18)F-FET through small-animal PET analyses. RESULTS: (18)F-AFETP demonstrated focally increased uptake in tumors with good visualization. Peak tumor uptake occurred within 10 min of injection, with stable or gradual decrease over time. All 3 tracers demonstrated relatively high uptake in the DBTs throughout the study. At late time points (47.5-57.5 min after injection), the average standardized uptake value with (18)F-FDG (1.9 ± 0.1) was significantly greater than with (18)F-FET (1.1 ± 0.1) and (18)F-AFETP (0.7 ± 0.2). The uptake also differed substantially in normal brain, with significant differences in the standardized uptake values at late times among (18)F-FDG (1.5 ± 0.2), (18)F-FET (0.5 ± 0.05), and (18)F-AFETP (0.1 ± 0.04). The resulting average tumor-to-brain ratio at the late time points was significantly higher for (18)F-AFETP (7.5 ± 0.1) than for (18)F-FDG (1.3 ± 0.1) and (18)F-FET (2.0 ± 0.3). CONCLUSION: (18)F-AFETP is a promising brain tumor imaging agent, providing rapid and persistent tumor visualization, with good tumor-to-normal-brain ratios in the DBT glioma model. High tumor-to-brain, tumor-to-muscle, and tumor-to-blood ratios were observed at 30 and 60 min after injection, with higher tumor-to-brain ratios than obtained with (18)F-FET or (18)F-FDG. These results support further development and evaluation of (18)F-AFETP and its derivatives for tumor imaging.
UNLABELLED: The goal of this study was to evaluate the (18)F-labeled nonnatural amino acid (S)-2-amino-3-[1-(2-(18)F-fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid ((18)F-AFETP) as a PET imaging agent for brain tumors and to compare its effectiveness with the more-established tracers O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) and (18)F-FDG in a murine model of glioblastoma. The tracer (18)F-AFETP is a structural analog of histidine and is a lead compound for imaging cationic amino acid transport, a relatively unexplored target for oncologic imaging. METHODS: (18)F-AFETP was prepared using the click reaction. BALB/c mice with intracranially implanted delayed brain tumor (DBT) gliomas (n = 4) underwent biodistribution and dynamic small-animal PET imaging for 60 min after intravenous injection of (18)F-AFETP. Tumor and brain uptake of (18)F-AFETP were compared with those of (18)F-FDG and (18)F-FET through small-animal PET analyses. RESULTS: (18)F-AFETP demonstrated focally increased uptake in tumors with good visualization. Peak tumor uptake occurred within 10 min of injection, with stable or gradual decrease over time. All 3 tracers demonstrated relatively high uptake in the DBTs throughout the study. At late time points (47.5-57.5 min after injection), the average standardized uptake value with (18)F-FDG (1.9 ± 0.1) was significantly greater than with (18)F-FET (1.1 ± 0.1) and (18)F-AFETP (0.7 ± 0.2). The uptake also differed substantially in normal brain, with significant differences in the standardized uptake values at late times among (18)F-FDG (1.5 ± 0.2), (18)F-FET (0.5 ± 0.05), and (18)F-AFETP (0.1 ± 0.04). The resulting average tumor-to-brain ratio at the late time points was significantly higher for (18)F-AFETP (7.5 ± 0.1) than for (18)F-FDG (1.3 ± 0.1) and (18)F-FET (2.0 ± 0.3). CONCLUSION: (18)F-AFETP is a promising brain tumor imaging agent, providing rapid and persistent tumor visualization, with good tumor-to-normal-brain ratios in the DBTglioma model. High tumor-to-brain, tumor-to-muscle, and tumor-to-blood ratios were observed at 30 and 60 min after injection, with higher tumor-to-brain ratios than obtained with (18)F-FET or (18)F-FDG. These results support further development and evaluation of (18)F-AFETP and its derivatives for tumor imaging.
Authors: Wenchao Qu; Zhihao Zha; Karl Ploessl; Brian P Lieberman; Lin Zhu; David R Wise; Craig B Thompson; Hank F Kung Journal: J Am Chem Soc Date: 2010-12-29 Impact factor: 15.419
Authors: Jonathan McConathy; Dong Zhou; Stephany E Shockley; Lynne A Jones; Elizabeth A Griffin; Hsiaoju Lee; Susan J Adams; Robert H Mach Journal: Mol Imaging Date: 2010-12 Impact factor: 4.488
Authors: Sarah C Jost; John E Wanebo; Sheng-Kwei Song; Michael R Chicoine; Keith M Rich; Thomas A Woolsey; Jason S Lewis; Robert H Mach; Jinbin Xu; Joel R Garbow Journal: Neurosurgery Date: 2007-02 Impact factor: 4.654
Authors: Eddie W F Lau; Katharine J Drummond; Robert E Ware; Elizabeth Drummond; Annette Hogg; Gail Ryan; Andrew Grigg; Jason Callahan; Rodney J Hicks Journal: J Clin Neurosci Date: 2009-12-09 Impact factor: 1.961
Authors: Dong Zhou; Wenhua Chu; Xin Peng; Jonathan McConathy; Robert H Mach; John A Katzenellenbogen Journal: Tetrahedron Lett Date: 2014-11-04 Impact factor: 2.415
Authors: Matthew B Nodwell; Hua Yang; Helen Merkens; Noeen Malik; Milena Čolović; Rainer E Martin; François Bénard; Paul Schaffer; Robert Britton Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057
Authors: Niklas von Spreckelsen; Colin M Fadzen; Nina Hartrampf; Yarah Ghotmi; Justin M Wolfe; Shipra Dubey; Bo Yeun Yang; Marie F Kijewski; Shuyan Wang; Charlotte Farquhar; Sonja Bergmann; Mykola Zdioruk; J Roscoe Wasserburg; Benjamin Scott; Emily Murrell; Fernanda C Bononi; Leonard G Luyt; Marcelo DiCarli; Martine L M Lamfers; Keith L Ligon; E Antonio Chiocca; Mariano S Viapiano; Bradley L Pentelute; Sean E Lawler; Choi-Fong Cho Journal: Adv Ther (Weinh) Date: 2021-01-20
Authors: Naresh Damuka; Miranda Orr; Paul W Czoty; Jeffrey L Weiner; Thomas J Martin; Michael A Nader; Avinash H Bansode; Buddhika S Liyana Pathirannahel; Akiva Mintz; Shannon L Macauley; Suzanne Craft; Kiran Kumar Solingapuram Sai Journal: Mol Biol Rep Date: 2021-04-20 Impact factor: 2.316
Authors: Tobias Borchert; Laura Beitar; Laura B N Langer; Andras Polyak; Hans-Jürgen Wester; Tobias L Ross; Denise Hilfiker-Kleiner; Frank M Bengel; James T Thackeray Journal: J Nucl Cardiol Date: 2019-10-28 Impact factor: 5.952